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Introduction
platinum wire to avoid movements and allow relaxation of the slice (Schleputz et al., 116 2011 ). Images were recorded by an analogue (JAI 2040; JAI Pulnix, Alzenau, Germany) 117 or a digital camera (IRB640; Visitron Systems, Munich, Germany) controlled by the 118 software program Optimas 6.5 (Optimas, Bothell, WA). A control picture was taken 119 before addition of any agonists or antagonists and frames were recorded every 30 sec. A 120 time interval of 5 minutes for cumulatively given doses and 20 minutes for single doses 121 were used. The images were analyzed by the image analysis program Optimas 6.5 122 (Optimas, Bothell, WA) . 123 124
Sensitization for antigen studies 125
For antigen studies with ovalbumin, the lung slices were incubated over night with cell 126 culture medium containing 1% serum from actively sensitized rats, as previously done 127 (Wohlsen et al., 2001 ). The medium was not changed until the following day. All other 128 lung slices were maintained in standard cell culture medium. Control studies were 129 performed to verify that 1% serum (of sensitized rats) did not interfere with responses 130 induced by other agonists and that ovalbumin did not show any effect in non-sensitised 131 slices. 132 133
Study design 134
Airway contractions to ovalbumin, PGD 2 , PGE 2 , the thromboxane receptor analogue 135 u46619, serotonin and methacholine were studied in rat PCLS. Effects of selective COX 136 inhibitors and selective EP 1 , EP 2 , EP 3 , EP 4 and TP receptor antagonists on airway tone 137
were assessed. The release of serotonin and prostanoids after ovalbumin-stimulation were 138 analysed in the supernatant. A single concentration of ovalbumin (10 µg/ml) was used for 139 antigen-induced contractions. This concentration was selected from a cumulative 140 concentration-response curve (0.01-1000 µg/ml of ovalbumin) ( Fig 1A) . The single dose 141 (10 µg/ml) of ovalbumin produced a strong, stable and reproducible bronchoconstriction 142 with the same maximum airway contraction as generated by cumulative challenge of 143 ovalbumin ( Fig 1B) . 144 145
Measurements of released mediators 146
Supernatant (0.5 ml) of six incubated PCLS (weight 0.03 g/slice) was collected and 147 immediately frozen at -80C. The samples were taken at three different time points. First 148 from unchallenged slices to obtain initial mediator release, thereafter, 20 minutes from 149 pre-treatment with the different drugs and finally 20 minutes after the slices were 150 challenged with 10 g/ml ovalbumin. Enzyme immunoassays of TXA 2 , PGD 2 , PGE 2 and 151 serotonin were performed according to the manufacturer's instructions. TXA 2 was 152 measured as the stable metabolite TXB 2 and PGD 2 as PGD 2 -mox. The assay detection 153 limits for the different mediators were 7.8 pg/ml for TXB 2 , PGD 2 , PGE 2 and 50 pg/ml for 154 serotonin. The enzyme immunoassay specificity for the different mediators to interfere 155 with each other was less than 0.01% for PGE 2 , PGD 2 -mox and serotonin, whereas the 156 antibody tracer for TXB 2 cross reacted with PGD 2 (0.53%) and with PGE 2 (0.09%). 157 158
RT-PCR analysis 159
PCLS were snap-frozen and pounded in liquid nitrogen. Total RNA was isolated from 30 160 mg lung powder with a NucleoSpin RNA II Kit (Machery Nagel GmbH & Co. KG, 161 Düren, Germany) automated on a QIAcube roboter (QIAGEN GmbH, Hilden, Germany) . 162 RNA was quantified in buffered 10 mM TRIS-HCl, pH 7.5, using a NanoDrop 1000 163 Spectrophotometer (Thermo Fisher Scientific Inc., Waltham (MA), USA). For reverse 164 transcription 274 ng of total RNA was added to 1 µl of oligo(dT) 15 Primer (0.5 µg/µl) 165 (Invitrogen, Karlsruhe, Germany) and water to a total volume of 12 µl. Samples were 166 incubated for 10 minutes at 65°C to linearize the RNA. 4 µl buffer (5x), 2 µl dNTP (10 167 mM), 1 µl Rnasin (40U/µl) and 1 µl M-MLV RT (H -) (200U/µl) (all substances from 168 Promega GmbH, Mannheim, Germany) were added and RNA was reverse transcribed for 169 90 minutes at 40°C. This was followed by a 2 minutes heat-inactivation step at 95°C. 20 170 µl of water was added afterwards to a final volume of 40 µl per sample. All incubation 171 steps were performed on a Biometra UNO II Thermocycler (Biometra GmbH, Göttingen, 172
Germany). For real-time qPCR 1 µl of cDNA was incubated as template with 0.5 µl 173 forward primer (6.25 µM) (Eurofins MWG GmbH, Ebersberg, Germany), 0.5 µl reverse 174 primer (6.25 µM), 5 µL SYBR-Green I Mastermix (Roche-Diagnostics GmbH, 175
Mannheim, Germany) and 3 µL water according to manufacturer's instructions in a 176
LightCycler 480 (Roche-Diagnostics GmbH). Following primer pairs were used for 5-177 (BAYu3405, Ramatroban) was purchased from Bayer AG (Wuppertal, Germany). PGD 2 , 199 PGE 2 , 9,11-dideoxy-9α,11α-methanoepoxy PGF 2α (U46619), 9-oxo-6-propan-2-200 yloxyxanthene-2-carboxylic acid (AH6809) and N- [[4'-[[3-butyl-1,5-dihydro-5- 
Effect of the COX pathway on ovalbumin-induced contractions 232
Ovalbumin (10 µg/ml) generated a stable and reproducible airway bronchoconstriction 233 (Fig 1A) . The antigen-induced contractions to ovalbumin (10 µg/ml) were significantly 234 attenuated by the unselective COX inhibitor indomethacin (10 µM; P=0.012; Fig 2A) , the 235 selective COX-1 inhibitor FR-122047 (5 µM; P=0.016; Fig 2B) and the selective COX-2 236 inhibitor celecoxib (10 µM; P=0.044; Fig 2C) inhibited the contractile response to ovalbumin ( Fig 3F) . 261 262
Synthesis of serotonin and prostanoids after challenge with ovalbumin 263
The supernatant was analysed to verify if there were any changes in generation of 264 serotonin and prostaglandins after ovalbumin stimulation and COX inhibition. The 265 medium contained relatively high levels of PGE 2 , TXB 2 and PGD 2 that were not changed 266 after stimulation by ovalbumin. The COX inhibitors indomethacin (10 µM) and celecoxib 267 (10 µM) significantly decreased the formation of PGE 2 , TXB 2 and PGD 2 , whereas the 268 COX-1 inhibitor FR-122047 (5 µM) significantly reduced the synthesis of TXB 2 ( Fig 4C)  269 and PGD 2 (Fig 4D) , but not PGE 2 (Fig 4B) . The formation of serotonin was significantly 270 increased after addition of ovalbumin 10 µg/ml (P=0.032). Notably, its synthesis or 271 release was not affected by the different COX inhibitors (Fig 4A) . In addition, pre-272 incubation with COX inhibitors or EP receptor antagonists did not change the initial 273 airway size in PCLS, indicating no direct effect on airway tone. 274 275
Effect of the COX pathway on serotonin-induced contractions 276
Since serotonin was the major contractile mediator of the antigen-induced response, the 277 effect of COX and prostanoids on serotonin-induced contractions was also evaluated to 278 investigate potential downstream modulations. Indomethacin (10 µM HT 2A receptor after 4h (Fig 6) . 298 299
Effect of COX inhibition and EP 1 receptor antagonism on methacholine-induced 300 contractions 301
To determine if the effect of COX inhibition and EP 1 receptor antagonism was specific to 302 serotonin rather than a general property of rat airways, methacholine-induced 303 bronchoconstriction was evaluated in the presence and absence of the COX inhibitor 304 indomethacin (10 µM) or the EP 1 receptor antagonist ONO-8713 (10 µM). The 305 contractions to methacholine were not altered by either indomethacin or ONO-8713 (Fig  306   7) . 307 308
Discussion 309
In this study, we present evidence that in the early allergic airway response in rat; 310 especially PGE 2 may act both as a primary mediator of antigen-induced airway 311 contraction via COX and the EP 1 and EP 4 receptors and as a downstream modulator of 312 serotonin-induced bronchoconstriction via COX-2 and the EP 1 receptor after antigen 313 challenge. Previous studies have indicated that prostanoids and serotonin are involved in 314 the early allergic airway response in the rat (Dahlback et al., 1984; Hele et al., 2001; 315 Nagase et al., 1996; Wohlsen et al., 2001 ). The relative contributions of these mediators, 316 however, remained uncertain. In the rat PCLS, the antigen-induced contractions to 317 ovalbumin were significantly attenuated by selective COX-1 and COX-2 inhibitors, 318 suggesting a role for both isoenzymes in the peripheral rat lung during the early allergic 319 airway response. Both COX-1 and COX-2 have been shown to be constitutively 320 expressed in the normal rat lung (Ermert et al., 1998b) with high enzyme activity (Baber 321 et al., 2003; Ermert et al., 1998a) , suggesting a crucial role for COX isoenzymes in the 322 regulation of pulmonary responses. The beneficial effect of COX inhibition during the 323 antigen response in the rat PCLS was somewhat surprising and opposite to other studies, 324 since in other models COX inhibition resulted in airway hyperresponsiveness and 325 increased contractility (Larsson et al., 2005; Peebles et al., 2002; Watts and Cohen, 326 1993) . On the other hand, leukotrienes, the major mediators in COX-sensitive asthma, 327 play only a minor role in rat PCLS (Wohlsen et al., 2001) , which may explain the 328 influence on the AHR and contractility. In addition, passively sensitized PCLS represents 329 a mast-cell dependent model to study mainly early allergic airway responses (Ressmeyer 330 et al., 2006; Wohlsen et al., 2001) . 331
To understand the attenuated antigen-induced bronchoconstriction after COX-332 inhibition, the effect of the prostanoids PGD 2 , PGE 2 and thromboxane was investigated 333 on rat airway tone, where only the TP receptor agonist u46619 induced some 334 contractions. Prostanoid receptors show considerable versatility and may mediate 335 bronchoconstriction via both TP and EP 1 receptors (Lydford and McKechnie, 1994) and 336 bronchodilatory effects through DP 1 , EP 2 and EP 4 receptors (Hartney et al., 2006; Norel 337 et al., 2004; Tilley et al., 2003) . Therefore, to further investigate the reduced contractile 338 response after COX-inhibition, we focused on the prostanoid receptors EP 1-4 and the TP 339 protein Gs or Gi (Feng et al., 2006) . 356
In addition, also the TP receptor antagonist partly affected the antigen-response, 357
indicating that TP receptors may contribute as well. Both TXA 2 and PGD 2 are known to 358 mediate airway contractions via the TP receptor (Larsson et al., 2011; McKenniff et al., 359 1991) , whereas PGD 2 may also cause bronchodilation via the DP 1 receptor (Larsson et 360 al., 2011; Norel et al., 1999) . Despite the pharmacological evidence of prostanoid 361 involvement in the early allergic airway response, supernatant levels of TXB 2 , PGD 2 or 362 PGE 2 were not increased after antigen challenge. COX inhibition significantly but not 363 completely reduced the generation of the prostanoids in the rat PCLS. The release of 364 serotonin was significantly increased after addition of ovalbumin and remained 365 unaffected by the different COX inhibitors. These data raised the hypothesis that 366 prostanoids may act as modulators of airway responsiveness. Since the 5-HT receptor 367 antagonist ketanserin completely blocked the antigen-induced contractions in the rat 368 PCLS, we hypothesised that serotonin is the main mediator of EAR and that the COX 369 metabolites may modulate the serotonin response. We observed that serotonin-induced 370 bronchoconstriction was attenuated by selective COX-2 inhibition and EP 1 antagonism, 371 whereas in contrast to the antigen-induced response, COX-1 inhibition had no effect. The 372 EP 2 and EP 4 receptor antagonist may also affect the serotonin-induced constriction. This 373 may result is probably depending on the fact that the EP 2 receptor antagonist has similar 374 affinity to the EP 1 receptor (Buckley et al., 2011) . However, apart from the EP 3 receptor 375 antagonist, the other EP receptor antagonists shifted the concentration-response curve to 376 the right. This is in line with the dilatory response via EP 2 and EP 4 on smooth muscle 377 cells. For EP 1 antagonism, the strongest effect was found, when both EP 2 and EP 4 378 receptors were triggered by endogenous PGE 2 produced by the PCLS during challenge. 379
In cases where either the EP 2 or EP 4 receptor was blocked this relaxation was reduced. 380
Again the EP 3 receptor seems to play a minor role also in smooth muscle cells. 381
Interestingly, the EP 2-4 receptors have been found on human smooth muscle cells (Mori et 382 al., 2011) . From our data, we would assume that the EP 1 receptor must have a role on 383 smooth muscle cells or mast cells, maybe only in the rat species. 384
Our data support the notion that the generation of PGE 2 was due to COX-2, as the 385 potent COX-1 inhibitor FR-122047 (Ochi and Goto, 2002) showed no effect on PGE 2 386 production in this study. In line with this, PGE 2 has been described to be generated in 387 high amounts by the COX-2 pathway in alveolar epithelium cells and airway smooth 388 muscle cells (Belvisi et al., 1997) . The present findings suggest that during the EAR, 389 serotonin-induced bronchoconstriction is enhanced by COX-2 derived PGE 2 acting on 390 EP 1 receptors in the rat lung. As the methacholine-induced bronchoconstriction was not 391 altered by either COX inhibition or EP 1 antagonism, the interaction between serotonin 392
and PGE 2 appears to be specific for serotonin. Similar findings have been reported from 393 other disease models (Sato et al., 2000; Xie et al., 2003) , that also implicated that 5-HT 394 responses may in part be mediated by the release of prostaglandins and associated with 395 COX-2 expression. It is possible that PGE 2 , formed either in response to allergen or 5-HT 396 receptor activation, interacts at the cellular signalling level with 5-HT 2A receptor-induced 397 responses (Berg et al., 1998; Selbie and Hill, 1998) . This hypothesis is supported by the 398 present finding that COX-inhibition enhanced 5-HT 2A receptor expression in the rat 399
PCLS. 400
Thus, while there is some evidence that the COX-2-derived prostanoids might at 401 least to some extent have been produced in epithelial and smooth muscle cells, it is 402 tempting to speculate that the effect of the COX-1 inhibitor was occurring in mast cells 403 that contain both COX-1 and COX-2 (Ermert et al., 1998b ). This speculation is based on 404 our observation that the COX-1 inhibitor had no effect on serotonin-induced 405 bronchoconstriction or 5-HT2AR expression in the present study, and on the finding that 406 COX-2 inhibitors had no effect on antigen-induced release of PGD 2 from rat mast cells 407 (Lau and Stenton, 1998). Unfortunately, high basal levels of PGE 2 , TXB 2 and PGD 2 in 408 the supernatant of the lung slices, made it difficult to interpret the findings in 
Conclusions 416
The major aim of this study was to evaluate the role of COX isoenzymes and prostanoids 417 in antigen-induced airway contractions of the peripheral rat lung. Since the preparation of 418 PCLS is essentially the same in all species; this model also provides the opportunity to 419 compare the early allergic airway response in different species. In guinea pig and human 420 PCLS, both prostanoids and histamine contribute to the allergen-induced 421 bronchoconstriction (Ressmeyer et al., 2006) . In the rat PCLS, where the allergen-422 induced bronchoconstriction is almost exclusively mediated by serotonin, the antigen-423 response appears to be modulated by locally formed prostanoids, in particular by PGE 2 , 424 derived from COX-2 and to some extent from COX-1. Apparently, the mechanisms by 425 which prostanoids contribute to the early allergic airway response differ among species. 
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